Altshuler Shaham Ltd Sells 25,267 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Altshuler Shaham Ltd decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 196,263 shares of the company's stock after selling 25,267 shares during the quarter. Teva Pharmaceutical Industries comprises approximately 0.1% of Altshuler Shaham Ltd's investment portfolio, making the stock its 27th biggest position. Altshuler Shaham Ltd's holdings in Teva Pharmaceutical Industries were worth $4,360,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Oarsman Capital Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $29,000. Wilmington Savings Fund Society FSB bought a new position in Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $66,000. IFP Advisors Inc boosted its stake in shares of Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its position in Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after purchasing an additional 949 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Analyst Ratings Changes

TEVA has been the topic of a number of research reports. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Barclays reduced their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Finally, Bank of America reduced their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Trading Up 4.9 %

Shares of Teva Pharmaceutical Industries stock traded up $0.66 on Tuesday, reaching $13.97. 4,650,883 shares of the company's stock were exchanged, compared to its average volume of 9,891,604. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a market capitalization of $15.83 billion, a P/E ratio of -9.64, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The firm's 50-day moving average is $15.39 and its two-hundred day moving average is $17.65. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.